BNB Plus (BNBX) Q1 2025 earnings summary

Executive summary

• Initiated a strategic restructuring to focus on synthetic DNA manufacturing via LineaRx, exiting the DNA tagging and security products segment and reducing workforce by 20%.

• Completed and certified GMP Site 1 facility for commercial operation, enabling enzymatic manufacture of DNA for mRNA clinical trial materials.

• October 2024 financing and warrant exercises bolstered cash reserves to support LineaRx's growth and execution in fiscal 2025.

• Leadership changes include new President and President of LineaRx to drive operational excellence and business development.

• Strategic restructuring aims to lower cash burn and stabilize financial position for near-term operational goals.

Financial highlights

• Q1 fiscal 2025 revenue was $1.2 million, up 34% year-over-year from $891,000, driven by higher product revenues and increased isotopic testing services.

• Gross profit rose 196% year-over-year to $684,107, with gross margin improving to 57% from 26%.

• Operating loss improved to $3 million from $3.8 million year-over-year due to lower SG&A and consulting expenses.

• Net loss was $2.7 million, compared to $1.1 million in the prior year, with adjusted EBITDA at negative $2.9 million, an improvement from negative $3.2 million.

• Cash and equivalents at December 31, 2024, were $9.3 million, rising from $6.4 million at September 30, 2024.

Outlook and guidance

• Fiscal 2025 expected to be a year of execution for LineaRx, with a robust sales pipeline for GMP IVT templates and new product launches.

• Anticipates multiple customer projects entering the clinic in 2025 and expansion of GMP manufacturing contracts.

• Focused on commercializing GMP Site 1 DNA production capacity and preparing for initial clinical-grade material orders.

• Expects workforce reduction to yield a 13% annual payroll cost reduction, offset by $300,000 in one-time separation costs in Q2 FY2025.

• Management remains engaged in a strategic review of the MDx Testing Services segment.